Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Bought by BNP Paribas Financial Markets

BNP Paribas Financial Markets lifted its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAKFree Report) by 416.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 3,220 shares of the company’s stock after acquiring an additional 2,596 shares during the period. BNP Paribas Financial Markets’ holdings in Takeda Pharmaceutical were worth $46,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of TAK. EverSource Wealth Advisors LLC grew its position in Takeda Pharmaceutical by 38.6% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company’s stock worth $43,000 after purchasing an additional 859 shares during the last quarter. Smithfield Trust Co boosted its position in shares of Takeda Pharmaceutical by 76.9% during the third quarter. Smithfield Trust Co now owns 3,428 shares of the company’s stock worth $49,000 after buying an additional 1,490 shares during the period. Headlands Technologies LLC bought a new position in Takeda Pharmaceutical in the 2nd quarter worth approximately $59,000. Hexagon Capital Partners LLC increased its position in Takeda Pharmaceutical by 34.3% in the 3rd quarter. Hexagon Capital Partners LLC now owns 4,419 shares of the company’s stock valued at $63,000 after acquiring an additional 1,129 shares during the period. Finally, Blue Trust Inc. raised its stake in Takeda Pharmaceutical by 74.0% during the 2nd quarter. Blue Trust Inc. now owns 5,480 shares of the company’s stock valued at $76,000 after acquiring an additional 2,330 shares in the last quarter. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Trading Down 0.8 %

NYSE:TAK opened at $13.01 on Friday. The stock has a market cap of $41.40 billion, a price-to-earnings ratio of 22.43, a PEG ratio of 0.25 and a beta of 0.51. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.77 and a current ratio of 1.28. Takeda Pharmaceutical Company Limited has a 1 year low of $12.57 and a 1 year high of $15.08. The business has a fifty day moving average of $13.72 and a 200-day moving average of $13.88.

About Takeda Pharmaceutical

(Free Report)

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.

Featured Articles

Institutional Ownership by Quarter for Takeda Pharmaceutical (NYSE:TAK)

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.